JP2014534218A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534218A5
JP2014534218A5 JP2014538927A JP2014538927A JP2014534218A5 JP 2014534218 A5 JP2014534218 A5 JP 2014534218A5 JP 2014538927 A JP2014538927 A JP 2014538927A JP 2014538927 A JP2014538927 A JP 2014538927A JP 2014534218 A5 JP2014534218 A5 JP 2014534218A5
Authority
JP
Japan
Prior art keywords
binding protein
tnf
fragment
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014538927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061690 external-priority patent/WO2013063114A1/en
Publication of JP2014534218A publication Critical patent/JP2014534218A/ja
Publication of JP2014534218A5 publication Critical patent/JP2014534218A5/ja
Pending legal-status Critical Current

Links

JP2014538927A 2011-10-24 2012-10-24 Tnfを標的とする免疫結合剤 Pending JP2014534218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550587P 2011-10-24 2011-10-24
US61/550,587 2011-10-24
PCT/US2012/061690 WO2013063114A1 (en) 2011-10-24 2012-10-24 Immunobinders directed against tnf

Publications (2)

Publication Number Publication Date
JP2014534218A JP2014534218A (ja) 2014-12-18
JP2014534218A5 true JP2014534218A5 (enExample) 2015-12-17

Family

ID=47144149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014538927A Pending JP2014534218A (ja) 2011-10-24 2012-10-24 Tnfを標的とする免疫結合剤

Country Status (26)

Country Link
US (2) US9803009B2 (enExample)
EP (1) EP2771362A1 (enExample)
JP (1) JP2014534218A (enExample)
KR (1) KR20140084253A (enExample)
CN (1) CN104093739A (enExample)
AR (1) AR088512A1 (enExample)
AU (1) AU2012328921B2 (enExample)
BR (1) BR112014009799A2 (enExample)
CA (1) CA2853357A1 (enExample)
CL (1) CL2014001054A1 (enExample)
CO (1) CO7020873A2 (enExample)
CR (1) CR20140225A (enExample)
DO (1) DOP2014000083A (enExample)
EC (1) ECSP14001249A (enExample)
HK (1) HK1200464A1 (enExample)
IL (1) IL232129A0 (enExample)
IN (1) IN2014CN03936A (enExample)
MX (1) MX2014004981A (enExample)
PE (1) PE20141545A1 (enExample)
PH (1) PH12014500866A1 (enExample)
RS (1) RS20140203A1 (enExample)
RU (1) RU2014120755A (enExample)
SG (1) SG11201401774VA (enExample)
TW (1) TW201326207A (enExample)
UY (1) UY34409A (enExample)
WO (1) WO2013063114A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
CN104093739A (zh) 2011-10-24 2014-10-08 艾伯维公司 针对tnf的免疫结合剂
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
HK1216894A1 (zh) * 2012-12-28 2016-12-09 Abbvie Inc. 多價結合蛋白組合物
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017048699A2 (en) * 2015-09-14 2017-03-23 Galaxy Biotech Llc Highly potent monoclonal antibodies to angiogenic factors
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
ES2877548T3 (es) 2016-06-02 2021-11-17 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
JP2019537600A (ja) * 2016-11-02 2019-12-26 ナノプロティアジェン, リミテッド ポリマーナノ粒子
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN107903323B (zh) * 2017-11-15 2020-04-17 中国药科大学 抗hTNF-α全人源抗体及其用途
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2023205739A2 (en) * 2022-04-20 2023-10-26 Senti Biosciences, Inc. Antigen-binding domains and methods of use thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
ZA94916B (en) 1993-02-10 1995-08-10 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス,インコーポレイテッド 大ゲノムdna欠失の生成
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク. 治療薬としてのcd147結合分子
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
ES2405551T3 (es) 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2004063335A2 (en) 2003-01-08 2004-07-29 Applied Molecular Evolution TNF-α BINDING MOLECULES
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
BRPI0511448A (pt) 2004-07-06 2007-12-26 Bioren Inc anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012025568A2 (pt) 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
CN104093739A (zh) 2011-10-24 2014-10-08 艾伯维公司 针对tnf的免疫结合剂
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
WO2014144299A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα

Similar Documents

Publication Publication Date Title
JP2014534218A5 (enExample)
RU2014120755A (ru) Иммуносвязующие агенты, направленные против tnf
JP2015502145A5 (enExample)
JP2020534830A5 (enExample)
JP2009005695A5 (enExample)
JP2017514461A5 (enExample)
JP2009517057A5 (enExample)
JP2013519364A5 (enExample)
JP7778701B2 (ja) 抗st2抗体及びその適用
JP2011527899A5 (enExample)
JP2012501670A5 (enExample)
JP2010042025A5 (enExample)
JPWO2019175217A5 (enExample)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2017535257A5 (enExample)
JP2011518546A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2012532851A5 (enExample)
CA2890455A1 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JPWO2019175215A5 (enExample)
JPWO2019175226A5 (enExample)
RU2014121043A (ru) Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
JPWO2019175224A5 (enExample)
JPWO2019175220A5 (enExample)
RU2012103212A (ru) Tlr3 связывающие агенты